What is Citius Pharmaceuticals Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Citius Pharmaceuticals's cash to debt ratio for the quarter that ended in Dec. 2023 was 47.43.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Citius Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.
The historical rank and industry rank for Citius Pharmaceuticals's Cash-to-Debt or its related term are showing as below:
CTXR'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03 Med: 44.12 Max: No Debt
Current: 47.43
During the past 13 years, Citius Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 0.03. And the median was 44.12.
Citius Pharmaceuticals Cash-to-Debt Historical Data
The historical data trend for Citius Pharmaceuticals's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Citius Pharmaceuticals Cash-to-Debt Chart
|
Citius Pharmaceuticals Annual Data
|
|
Trend |
Sep14 |
Sep15 |
Sep16 |
Sep17 |
Sep18 |
Sep19 |
Sep20 |
Sep21 |
Sep22 |
Sep23 |
| Cash-to-Debt |
|
Get a 7-Day Free Trial
|
|
|
45.63 |
10.25 |
81.96 |
61.52 |
55.05 |
|
Citius Pharmaceuticals Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
58.46 |
49.94 |
62.44 |
55.05 |
47.43 |
Competitive Comparison of Citius Pharmaceuticals's Cash-to-Debt
For the Biotechnology subindustry, Citius Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Citius Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Citius Pharmaceuticals's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Citius Pharmaceuticals's Cash-to-Debt falls into.
Citius Pharmaceuticals Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Citius Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Sep. 2023 is calculated as:
Citius Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Citius Pharmaceuticals (Citius Pharmaceuticals) Business Description
Traded in Other Exchanges
Address
11 Commerce Drive, First Floor, Cranford, NJ, USA, 07016
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
Executives
| Myron Z Holubiak |
director, officer: Vice Chairman |
C/O CITIUS PHARMACEUTICALS, INC., 63 GREAT ROAD, MAYNARD MA 01754 |
| Dennis M Mcgrath |
director |
C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165 |
| Leonard L Mazur |
director, 10 percent owner, officer: Chief Executive Officer |
C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016 |
| Suren G Dutia |
director |
C/O CITIUS PHARMACEUTICALS, INC., 63 GREAT ROAD, MAYNARD MA 01754 |
| Carol Webb |
director |
11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD NJ 07016 |
| Eugene Myron Holuka |
director |
11 COMMERCE DRIVE, 11TH FLOOR, CRANFORD NJ 07016 |
| Jaime Bartushak |
officer: Chief Financial Officer |
C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016 |
| Myron Czuczman |
officer: Chief Medical Officer |
C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016 |
| Howard Safir |
director |
11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD NJ 07016 |
| William Kane |
director |
11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD NJ 07016 |
Citius Pharmaceuticals (Citius Pharmaceuticals) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CTXR has been successfully added to your